As SGLT2-i medications continue to show promising benefits for improving clinical outcomes for individuals without diabetes who have heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and chronic kidney disease, prescription of SGLT2-i medications has increased substantially for these indications, including a 12-fold increase in monthly prescribing by cardiologists between 2015 and 2020 [20, 39, 40]. This evidence concerns the gene SLC5A2 and chronic kidney disease.